{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:11:40Z","timestamp":1790745100977,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T00:00:00Z","timestamp":1555372800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hum Genomics"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40246-019-0203-9","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T09:04:44Z","timestamp":1555405484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Mutations in ATP13A2 (PARK9) are associated with an amyotrophic lateral sclerosis-like phenotype, implicating this locus in further phenotypic expansion"],"prefix":"10.1186","volume":"13","author":[{"given":"Rossella","family":"Spataro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sali M. K.","family":"Farhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Willer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay P.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Dion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy A.","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Neale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"La Bella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2480-0171","authenticated-orcid":false,"given":"Nicholas","family":"Katsanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,16]]},"reference":[{"key":"203_CR1","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s13059-016-1099-5","volume":"17","author":"R Shaheen","year":"2016","unstructured":"Shaheen R, et al. Characterizing the morbid genome of ciliopathies. Genome Biol. 2016;17:242.","journal-title":"Genome Biol"},{"key":"203_CR2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.5607\/en.2014.23.4.314","volume":"23","author":"T Lopes da Fonseca","year":"2014","unstructured":"Lopes da Fonseca T, Outeiro TF. ATP13A2 and alpha-synuclein: a metal taste in autophagy. Exp Neurobiol. 2014;23:314\u201323.","journal-title":"Exp Neurobiol"},{"key":"203_CR3","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1080\/15384101.2015.1093420","volume":"14","author":"S Martin","year":"2015","unstructured":"Martin S, Holemans T, Vangheluwe P. Unlocking ATP13A2\/PARK9 activity. Cell Cycle. 2015;14:3341\u20132.","journal-title":"Cell Cycle"},{"key":"203_CR4","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.bbrc.2004.08.156","volume":"323","author":"PJ Schultheis","year":"2004","unstructured":"Schultheis PJ, et al. Characterization of the P5 subfamily of P-type transport ATPases in mice. Biochem Biophys Res Commun. 2004;323:731\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"203_CR5","doi-asserted-by":"crossref","unstructured":"van Veen S, et al. Cellular function and pathological role of ATP13A2 and related P-type transport ATPases in Parkinson's disease and other neurological disorders. Front Mol Neurosci. 2014;7(48):48e1-e22.","DOI":"10.3389\/fnmol.2014.00048"},{"key":"203_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1600-0404.1994.tb02645.x","volume":"89","author":"AS Najim al-Din","year":"1994","unstructured":"Najim al-Din AS, Wriekat A, Mubaidin A, Dasouki M, Hiari M. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol Scand. 1994;89:347\u201352.","journal-title":"Acta Neurol Scand"},{"key":"203_CR7","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/ng1884","volume":"38","author":"A Ramirez","year":"2006","unstructured":"Ramirez A, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet. 2006;38:1184\u201391.","journal-title":"Nat Genet"},{"key":"203_CR8","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1002\/mds.22996","volume":"25","author":"MI Behrens","year":"2010","unstructured":"Behrens MI, et al. Clinical spectrum of Kufor-Rakeb syndrome in the Chilean kindred with ATP13A2 mutations. Mov Disord. 2010;25:1929\u201337.","journal-title":"Mov Disord"},{"key":"203_CR9","first-page":"99","volume":"21","author":"HJ Lai","year":"2012","unstructured":"Lai HJ, Lin CH, Wu RM. Early-onset autosomal-recessive parkinsonian-pyramidal syndrome. Acta Neurol Taiwanica. 2012;21:99\u2013107.","journal-title":"Acta Neurol Taiwanica"},{"key":"203_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10048-010-0259-0","volume":"12","author":"L Santoro","year":"2011","unstructured":"Santoro L, et al. Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability. Neurogenetics. 2011;12:33\u20139.","journal-title":"Neurogenetics"},{"key":"203_CR11","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1093\/hmg\/dds089","volume":"21","author":"J Bras","year":"2012","unstructured":"Bras J, Verloes A, Schneider SA, Mole SE, Guerreiro RJ. Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis. Hum Mol Genet. 2012;21:2646\u201350.","journal-title":"Hum Mol Genet"},{"key":"203_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/BF00690197","volume":"68","author":"FM Tome","year":"1985","unstructured":"Tome FM, Brunet P, Fardeau M, Hentati F, Reix J. Familial disorder of the central and peripheral nervous systems with particular cytoplasmic lamellated inclusions in peripheral nerves, muscle satellite cells, and blood capillaries. Acta Neuropathol. 1985;68:209\u201317.","journal-title":"Acta Neuropathol"},{"key":"203_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/brain\/aww307","volume":"140","author":"A Estrada-Cuzcano","year":"2017","unstructured":"Estrada-Cuzcano A, et al. Loss-of-function mutations in the ATP13A2\/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78). Brain. 2017;140:287\u2013305.","journal-title":"Brain"},{"key":"203_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0005-2728(98)00041-3","volume":"1365","author":"MG Palmgren","year":"1998","unstructured":"Palmgren MG, Axelsen KB. Evolution of P-type ATPases. Biochim Biophys Acta. 1998;1365:37\u201345.","journal-title":"Biochim Biophys Acta"},{"key":"203_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.neuint.2017.11.008","volume":"112","author":"F Tezanos Pinto de","year":"2018","unstructured":"de Tezanos Pinto F, Adamo HP. The strategic function of the P5-ATPase ATP13A2 in toxic waste disposal. Neurochem Int. 2018;112:108\u201313.","journal-title":"Neurochem Int"},{"key":"203_CR16","doi-asserted-by":"publisher","first-page":"9040","DOI":"10.1073\/pnas.1508220112","volume":"112","author":"T Holemans","year":"2015","unstructured":"Holemans T, et al. A lipid switch unlocks Parkinson's disease-associated ATP13A2. Proc Natl Acad Sci U S A. 2015;112:9040\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"203_CR17","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/mds.26243","volume":"30","author":"JS Park","year":"2015","unstructured":"Park JS, Blair NF, Sue CM. The role of ATP13A2 in Parkinson's disease: clinical phenotypes and molecular mechanisms. Mov Disord. 2015;30:770\u20139.","journal-title":"Mov Disord"},{"key":"203_CR18","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1093\/hmg\/ddr606","volume":"21","author":"D Ramonet","year":"2012","unstructured":"Ramonet D, et al. PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity. Hum Mol Genet. 2012;21:1725\u201343.","journal-title":"Hum Mol Genet"},{"key":"203_CR19","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.nbd.2011.12.015","volume":"45","author":"AM Gusdon","year":"2012","unstructured":"Gusdon AM, Zhu J, Van Houten B, Chu CT. ATP13A2 regulates mitochondrial bioenergetics through macroautophagy. Neurobiol Dis. 2012;45:962\u201372.","journal-title":"Neurobiol Dis"},{"key":"203_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/ptj\/67.2.206","volume":"67","author":"RW Bohannon","year":"1987","unstructured":"Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67:206\u20137.","journal-title":"Phys Ther"},{"key":"203_CR21","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1212\/01.wnl.0000260963.08711.08","volume":"68","author":"A Fonzo Di","year":"2007","unstructured":"Di Fonzo A, et al. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology. 2007;68:1557\u201362.","journal-title":"Neurology"},{"key":"203_CR22","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/ng.3789","volume":"49","author":"JA Kosmicki","year":"2017","unstructured":"Kosmicki JA, et al. Refining the role of de novo protein-truncating variants in neurodevelopmental disorders by using population reference samples. Nat Genet. 2017;49:504\u201310.","journal-title":"Nat Genet"},{"key":"203_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa1516767","volume":"376","author":"JE Posey","year":"2017","unstructured":"Posey JE, et al. Resolution of disease phenotypes resulting from multilocus genomic variation. N Engl J Med. 2017;376:21\u201331.","journal-title":"N Engl J Med"}],"container-title":["Human Genomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-019-0203-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40246-019-0203-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-019-0203-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T19:28:00Z","timestamp":1586892480000},"score":1,"resource":{"primary":{"URL":"https:\/\/humgenomics.biomedcentral.com\/articles\/10.1186\/s40246-019-0203-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,16]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["203"],"URL":"https:\/\/doi.org\/10.1186\/s40246-019-0203-9","relation":{},"ISSN":["1479-7364"],"issn-type":[{"value":"1479-7364","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,16]]},"assertion":[{"value":"24 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients who participated in the study signed an informed consent and all samples were collected analyzed in accordance with the World Medical Association Declaration of Helsinki. This study was approved by the Ethics Committees of the University of Palermo and the Montreal Neurological Institute and Hospital (IRB00010120).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Resulting patient data have been de-identified and are suitable for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NK is a paid consultant of Rescindo Therapeutics. The remaining authors report no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"19"}}